Escherichia coli triggers α-synuclein pathology in the LRRK2 transgenic mouse model of PD

Gut Microbes. 2023 Dec;15(2):2276296. doi: 10.1080/19490976.2023.2276296. Epub 2023 Nov 27.

Abstract

Alpha-synuclein (α-syn) pathology is the hallmark of Parkinson's disease (PD). The leucine-rich repeat kinase 2 (LRRK2) gene is a major-effect risk gene for sporadic PD (sPD). However, what environmental factors may trigger the formation of α-syn pathology in carriers of LRRK2 risk variants are still unknown. Here, we report that a markedly increased abundance of Escherichia coli (E. coli) in the intestinal microbiota was detected in LRRK2 risk variant(R1628P or G2385R) carriers with sPD compared with carriers without sPD. Animal experiments showed that E. coli administration triggered pathological α-syn accumulation in the colon and spread to the brain via the gut-brain axis in Lrrk2 R1628P mice, due to the co-occurrence of Lrrk2 variant-induced inhibition of α-syn autophagic degradation and increased phosphorylation of α-syn caused by curli in E. coli-derived extracellular vesicles. Fecal microbiota transplantation (FMT) effectively ameliorated motor deficits and α-syn pathology in Lrrk2 R1628P mice. Our findings elaborate on the mechanism that E. coli triggers α-syn pathology in Lrrk2 R1628P mice, and highlight a novel gene-environment interaction pattern in LRRK2 risk variants. Even more importantly, the findings reveal the interplay between the specific risk gene and the matched environmental factors triggers the initiation of α-syn pathology in sPD.

Keywords: Escherichia coli; LRRK2; Parkinson’s disease; gene-environment interplay; α-synuclein pathology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Escherichia coli / genetics
  • Escherichia coli / metabolism
  • Gastrointestinal Microbiome*
  • Mice
  • Mice, Transgenic
  • Parkinson Disease* / genetics
  • Parkinson Disease* / pathology
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism

Substances

  • alpha-Synuclein

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (No. 82122022), the National Natural Science Foundation of China (No. 82171248), the Natural Science Foundation of Henan Province for Distinguished Young Scholars (No. 222300420017), the Henan Scientific and Technological Development Program (No. 232301420015), the Henan Province Young and Middle-Aged Health Science and Technology Innovation (No. YXKC2020033), the National Key Research and Development Program of China (No. 2021YFC2502100), the National Key Research and Development Program of China (No. 2021YFC2501200), the Young and Middle-aged Leading Academic Discipline Project of Henan Province, the Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University (No. ZYCXTD2023003), the Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University (No. QNCXTD2023008), the Clinical Medicine First-Class Discipline Talent Cultivation Program of Zhengzhou University (No. 32410700TP010) and the Natural Science Foundation of Henan Province (No. 202300410459).